Aripiprazole in Children With Autism: A Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00208533|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : March 29, 2017
This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism.
Children who qualify for the study will be treated with aripiprazole for 6 weeks.
Treatment is provided at no cost.
|Condition or disease||Intervention/treatment||Phase|
|Autism||Drug: Aripiprazole||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Masking Description:||The care provider is unaware of the treatment arm the child is enrolled.|
|Official Title:||Aripiprazole in Children With Autism: A Pilot Study|
|Study Start Date :||February 2004|
|Actual Primary Completion Date :||November 16, 2011|
|Actual Study Completion Date :||November 16, 2011|
1 Open Label
Open Label Aripiprazole
Aripiprazole 5 mg to 30mg, individually titrated
Other Name: Abilify
- Clinical Global Impressions [ Time Frame: Week 6 ]
- Children's Psychiatric Rating Scale [ Time Frame: Baseline, Week 6 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00208533
|United States, Pennsylvania|
|Drexel University College of Medicine at Friends Hospital|
|Philadelphia, Pennsylvania, United States, 19124|
|Principal Investigator:||Richard P Malone, MD||Drexel University College of Medicine|